Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Free prostate cancer screenings offered at disease awareness event

Rachel Soon
Medical Writer
27 Aug 2020

A local hospital is offering free screenings for prostate cancer to current and former patients as part of an awareness campaign for the disease.

Through July to September, Sunway Medical Centre (SunMed) and Sunway Medical Centre Velocity are offering the prostate-specific antigen (PSA) test and consultation for patients with suspected or confirmed prostate conditions, according to a press statement.

The campaign aims “to encourage men to step forward, recognize the early signs and symptoms, overcome common stigmas associated with the disease, take immediate steps to screen for prostate cancer and seek treatment accordingly to improve their quality of life,” said SunMed representatives.

According to the WHO, prostate cancer is the second most common cancer among men globally. In 2018, it accounted for 8.8 percent of all newly diagnosed cancers in Malaysian men, making it the third most common in the country after lung cancer (16.6 percent) and colorectal cancers (16.2 percent). [https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf]

“The growth in prostate cancer is also observed at [our centre]. In 2019, it emerged, for the first time in many years, as one of the top five cancers recorded at the hospital,” said Dr Seow Vei Ken, medical director at SunMed.

Compared to other cancers, prostate cancer may have the second highest overall 5-year relative survival (RS) rate. The Malaysian Study on Cancer Survival (MySCan) found a 5-year RS of 73 percent in patients diagnosed with prostate cancer between 2007 and 2011, with those diagnosed with Stage I to III cancers holding an RS of above 90 percent. However, RS dropped to 43.2 percent in patients with Stage IV cancers in the same report. [http://nci.moh.gov.my/index.php/ms/list-penerbitan/35-laporan/522-myscan]

“Getting over the stigma [of prostate cancer] is one of the first steps. Many men do not step forward out of fear of being judged. Consequently, the lack of early disclosure could prove detrimental,” said Dr Badrulhisham Bahadzor, consultant urologist at SunMed. “That is why we believe the combination of the free test, consultation with urologists, and complimentary webinars in [our] prostate cancer awareness campaign will make it easier for men to take that initial step.”

“With movement restrictions potentially easing in the months ahead, we invite those diagnosed, undergoing treatment as well as suspected with prostate conditions to come to SunMed for the free PSA test and consultation,” he added.

From June up till mid-July, teams from the hospital’s SunMed@Home programme were also dispatched to homes of prostate cancer survivors to collect blood samples for PSA testing. The free home service was offered to existing SunMed patients, including members of the Prostate Cancer Society Malaysia (PCSM).

“PSA tests are an important tool in detecting and monitoring the recurrence of prostate cancer,” said Wong Kuan Sing, PCSM acting president.

Wong, who was himself diagnosed 9 years ago with prostate cancer through a PSA screening, added that the free testing initiative was “timely, useful and crucial” given the current Recovery Movement Control Order (RMCO) in place nationwide.

As part of safety measures in place during the RMCO, the PCSM’s recent quarterly support group meeting was conducted virtually with the support of SunMed, with participants given the option to disable their video feeds for privacy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.